Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Nasdaq Virtual Investor Conference Transcript

Dec 04, 2020 / 04:00PM GMT
Release Date Price: $129.56 (-1.23%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning. My name is David Lebowitz. I'm 1 of the biotechnology analysts at Morgan Stanley. Before I get going, let me just read you the important disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please please reach out to your Morgan Stanley sales representative. I'd like to welcome you all once again to the 43rd NASDAQ Investor Conference, and I'm happy to have with me, from Alnylam Pharmaceuticals, CFO, Jeff Poulton. Jeff, thank you very much for being here. I guess before we get started, could you just give us a topline overview of Alnylam Pharmaceuticals, it's really a unique company, it's a platform-based company. You've had 3 drugs approved within the last 2 years, which is really quite remarkable. You have a unique technology called RNA interference could you tell us about the history, where it's come from and where it's going?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot